Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.

JAMA neurology - 1 Oct 2015

Monsell Sarah E, Kukull Walter A, Roher Alex E, Maarouf Chera L, Serrano Geidy, Beach Thomas G, Caselli Richard J, Montine Thomas J, Reiman Eric M

Abstract excerpt

IMPORTANCE: β-Amyloid peptide (Aβ) plaques are a cardinal neuropathologic feature of Alzheimer disease (AD), yet more than one-third of apolipoprotein E ε4 (APOE4) noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia may not meet positron emission tomographic criteria for significant cerebral amyloidosis. OBJECTIVES: To clarify the percentage of APOE4 carriers and noncarriers with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amyloid beta-Peptides

Share to Amyloid beta-Protein Precursor

Share to Apolipoprotein E4

Share to Genotype

Share to Neurofibrillary Tangles

Share to Plaque, Amyloid

Source

Open in PubMed Open full text

Identifiers

PMID: 26302353
DOI: 10.1001/jamaneurol.2015.1721
PMCID: PMC4833059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.PMID 26302353Read ↗

Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's diseaseSemantic proximity Read ↗

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.Semantic proximity Read ↗

Severity distribution of Alzheimer’s disease dementia and mild cognitive impairment in the Framingham Heart StudySemantic proximity Read ↗

The Effect of the APOE ε2ε4 Genotype on the Development of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in Non-Latino Whites.Semantic proximity Read ↗

Apolipoprotein E4, Amyloid, and Cognition in Alzheimer’s and Lewy Body DiseaseSemantic proximity Read ↗

Pathologically Confirmed Alzheimer's Disease in APOE ɛ2 Homozygotes is Rare but Does Occur.Semantic proximity Read ↗

APOE ε4–associated heterogeneity of neuroimaging biomarkers across the Alzheimer's disease continuumSemantic proximity Read ↗

APOEε2 is associated with milder clinical and pathological Alzheimer disease.Semantic proximity Read ↗

On Gaps of Clinical Diagnosis of Dementia Subtypes: A Study of Alzheimer’s Disease and Lewy Body DiseaseSemantic proximity Read ↗

Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.Semantic proximity Read ↗

APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.Semantic proximity Read ↗

The proportion of Alzheimer’s disease attributable to apolipoprotein ESemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.